Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"

From Libre Pathology
Jump to navigation Jump to search
(+ISH)
Line 38: Line 38:
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag.
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag.
</gallery>
</gallery>
==Molecular==
*Testing often done with dual-colour break apart FISH probes.<ref name=pmid27535289>{{cite journal |vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E |title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations |journal=Virchows Arch. |volume=469 |issue=5 |pages=489–503 |date=November 2016 |pmid=27535289 |pmc=5082594 |doi=10.1007/s00428-016-2000-3 |url=}}</ref>


==See also==
==See also==

Revision as of 02:49, 31 December 2019

Micrograph showing a ROS1-positive adenocarcinoma of the lung. ROS1 immunostain.

ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]

General

Microscopic

Features:

Note:

  • Most common pattern varies by specimen type:[4]
    • Biopsy specimens: solid pattern most common.
    • Resection specimens: acinar pattern most common.

Images

IHC

  • ROS1 +ve.

Images

Molecular

  • Testing often done with dual-colour break apart FISH probes.[5]

See also

References

  1. Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  2. "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
  3. "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
  4. 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.
  5. "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. November 2016. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/.